Lysyl oxidase (LOX) mRNA expression and genes of the differentiated osteoblastic phenotype are upregulated in human osteosarcoma cells by suramin

被引：6

作者：

Buchinger, B. ^{[1
,2
]}

Spitzer, S. ^{[1
,2
]}

Karlic, H. ^{[3
]}

Klaushofer, K. ^{[1
,2
]}

Varga, F. ^{[1
,2
]}

机构：

[1] Hanusch Hosp WGKK, Ludwig Boltzmann Inst Osteol, A-1140 Vienna, Austria

[2] Hanusch Hosp, AUVA Trauma Ctr Meidling, Dept Med 4, A-1140 Vienna, Austria

[3] Hanusch Hosp, Ludwig Boltzmann Inst Leukemia Res & Hematol, A-1140 Vienna, Austria

来源：

CANCER LETTERS | 2008年 / 265卷 / 01期

关键词：

osteosarcoma cells; suramin; lysyl oxidase; osteocalcin; telomerase activity;

D O I：

10.1016/j.canlet.2008.02.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It is well known that suramin influences proliferation and differentiation of tumour cells. To study whether and how suramin effects osteosarcoma (OS) cells, proliferation, differentiation, LOX mRNA expression and telomerase activity (TA) was analysed in the human MG-63 and U-2 OS, and the rat UMR-106 OS cell lines. Data show that suramin inhibited proliferation in the human cell lines and upregulated alkaline phosphatase activity. TA was attenuated in the human cells while in UMR-106 it was not changed. In UMR-106 suramin had no influence on osteocalcin and LOX expression, in the human cells however, both genes were upregulated. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：45 / 54

页数：10

共 58 条

[41] The propeptide domain of lysyl oxidase induces phenotypic reversion of Ras-transformed cells [J].

Palamakumbura, AH ;

Jeay, S ;

Guo, Y ;

Pischon, N ;

Sommer, P ;

Sonenshein, GE ;

Trackman, PC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (39) :40593-40600

[42] OSTEOPONTIN - A POSSIBLE ANCHOR OF OSTEOCLASTS TO BONE [J].

REINHOLT, FP ;

HULTENBY, K ;

OLDBERG, A ;

HEINEGARD, D .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) :4473-4475

[43]

Ren CZ, 1998, CANCER RES, V58, P1285

[44]

Schuetze Scott M, 2007, J Natl Compr Canc Netw, V5, P449

[45] Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone [J].

Small, EJ ;

Meyer, M ;

Marshall, ME ;

Reyno, LM ;

Meyers, FJ ;

Natale, RB ;

Lenehan, PF ;

Chen, L ;

Slichenmyer, WJ ;

Eisenberger, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) :1440-1450

[46]

Song SH, 2001, CANCER RES, V61, P6145

[47] RELATIONSHIP OF CELL-GROWTH TO THE REGULATION OF TISSUE-SPECIFIC GENE-EXPRESSION DURING OSTEOBLAST DIFFERENTIATION [J].

STEIN, GS ;

LIAN, JB ;

OWEN, TA .

FASEB JOURNAL, 1990, 4 (13) :3111-3123

[48] MOLECULAR MECHANISMS MEDIATING PROLIFERATION DIFFERENTIATION INTERRELATIONSHIPS DURING PROGRESSIVE DEVELOPMENT OF THE OSTEOBLAST PHENOTYPE [J].

STEIN, GS ;

LIAN, JB .

ENDOCRINE REVIEWS, 1993, 14 (04) :424-442

[49] Effect of IGF-I and PDGF administered in vivo on the expression of osteoblast-related genes in old rats [J].

Tanaka, H ;

Wakisaka, A ;

Ogasa, H ;

Kawai, S ;

Liang, CT .

JOURNAL OF ENDOCRINOLOGY, 2002, 174 (01) :63-70

[50] Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro [J].

Trieb, K ;

Blahovec, H .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (07) :1066-1070

← 1 2 3 4 5 6 →